Pharmaceuticals
2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting
SHANGHAI, Dec. 8, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versus-Host Disease (cGvHD) who have either progressed or not responded to one or mo...
2024-12-09 10:40
2083
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
BEIJING, SHANGHAI and BOSTON, Dec. 8, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (Ame...
2024-12-09 08:42
1909
Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
OSAKA, Japan and MONTREAL , Dec. 5, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters:Osaka, Japan; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters:Montreal, Quebec, Canada; CEO:...
2024-12-06 07:56
1869
China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke
NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been approved for marketing by the National Medical Products Admini...
2024-12-04 18:10
2633
Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer
HONG KONG, Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study (AK104-IIT-018) of cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced or metastat...
2024-12-04 13:09
2152
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery
* VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery * Statistically and clinically meaningful reductions in inflammation and ...
2024-12-04 00:00
2438
Terumo Interventional Systems Announces Launch of Its R2P NaviCross Peripheral Support Catheter
– Provides interventionalists with optimal product choices for more complex radial-to-peripheral procedures– SOMERSET, N.J., Dec. 3, 2024 /PRNewswire/ -- Terumo Interventional Systems (TIS), a division of Terumo Corporation, is pleased to announce the launch and commercial availability of its R2...
2024-12-03 21:00
1704
Samsung Biologics hosts ESG event with suppliers to strengthen decarbonization efforts
INCHEON, South Korea, Dec. 3, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today hosted its second Supplier ESG Day to share insights on sustainable management and encourage ESGactions among suppliers. Second of i...
2024-12-03 20:00
2007
Fangzhou Inc. Announces Inclusion of Its Shares in Hang Seng Hong Kong-Listed Biotech Index
HONG KONG, Dec. 3, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company's Ordinary Shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), will be included in the Hang Seng Hong Ko...
2024-12-03 18:47
1959
MGI Tech announces partnership with Universidad de San Martín de Porres to strengthen human genetics research
* The implementation of MGI Tech's next-generation genomic sequencing (NGS) technologies will strengthen scientific research in the country, enabling the identification of key genetic variations, contributing to disease prevention, and personalizing medical treatments. * A team of specialists...
2024-12-02 11:16
1793
BGM Group Ltd Pioneers Innovation in AI Technology, Fostering Holistic Integration of Healthcare and Insurtech
CHENGDU, China, Nov. 29, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), a leading global pharmaceutical enterprise, today announced its acquisition of the intelligent platform of AIX Inc. (NASDAQ: AIFU) ("AIX") valued at1 billion RMB (approximately $140 million). The ...
2024-11-29 23:58
5915
MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China
SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of its Phase III clinical trial of MRX-4 for injection transitioning to oral Contezolid tablets for the treatment of adult patients with complex sk...
2024-11-29 22:00
3355
Minghui Pharmaceutical Announces Positive Topline Results from Phase Ⅲ Trial of MH004 (Tofacitinib Etocomil) Ointment in Mild to Moderate Atopic Dermatitis
SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced positive topline results from its phase Ⅲ trial of MH004 (tofacitinib etocomil) ointment 1.0%, a twic...
2024-11-29 20:31
3627
Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference
HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce its participation in the upcoming 7th Annual Evercore HealthCONx Conference and Citi 2024 Global Healthcare Conference, both taking place inMiami. Akeso will participate in a firesid...
2024-11-29 10:23
1957
Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab
HONG KONG, Nov. 27, 2024 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce that two of its independently developed, globally pioneering bispecific antibody drugs—cadonilimab Injection (PD-1/CTLA-4 bispecific antibody) and ivonescimab Injection (PD-1/VEGF bi...
2024-11-28 11:58
2553
111, Inc. Announces Third Quarter 2024 Unaudited Financial Results
* Maintained Operational Profitability for the Third Consecutive Quarter * Operating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoY * Held Positive Operating Cash Flow for Three Consecutive Quarters SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company...
2024-11-27 14:00
2378
VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation
GUANGZHOU, China, Nov. 26, 2024 /PRNewswire/ -- VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, recently announced a strategic cooperation agreement. The collaboration ...
2024-11-26 22:00
2506
GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment
YONGIN, South Korea, Nov. 25, 2024 /PRNewswire/ -- GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial with 'GC1130A', an innovative new drug for Sanfillippo syndrome type A (MPS IIIA). GC Biopharma and Novel Pharma have...
2024-11-26 08:44
2284
Duality Biologics Announces Expansion of Adcendo ApS Collaboration Through Option Exercise of Strategic License Agreement
Adcendo ApS exercises its option to utilize Duality Biologics' platform to further enhance its first-in-class ADC pipeline PRINCETON, N.J., SHANGHAI and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Duality Biologics ("Duality"), a clinical-stage biotech company focusing on the discovery and deve...
2024-11-26 08:30
2163
ReviR Therapeutics and Kennedy's Disease Association Partner to Advance Treatment for Rare Neuromuscular Disorder
BRISBANE, Calif., Nov. 25, 2024 /PRNewswire/ -- ReviR Therapeutics, a pioneering biotechnology company focused on developing novel small molecule RNA modulators for neurogenetic diseases, announced a groundbreaking research grant from the Kennedy's Disease Association (KDA) to advance a therapy f...
2024-11-26 01:00
1856
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 316 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 300 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
Building the Run: Xtep Charts a New Community Ecosystem in Southeast Asia
2026-01-20 17:49
7287
